Beacon Roofing Supply, Inc. (NASDAQ:BECN) recorded a trading volume of 2.5 million shares, above its 90-day volume average of 0.82 million shares. The stock kicked off the session at $59.5 and later approached $58.98 with a change of 4.8%.Beacon Roofing Supply, Inc. (BECN) Analyst Opinion
Beacon Roofing Supply, Inc. has a consensus outperform rating from 16 Wall Street analysts, and the number of shares currently sold short amount to at least 4.34% of shares outstanding. The stock spiked 7.35% last month and is up 28.02 this year. Wall Street is only getting more bullish on the stock, with 12 of analysts who cover BECN having a buy-equivalent rating. Analysts have placed a $56.08 price target on Beacon Roofing Supply, Inc., suggesting a -4.92% decline from recent close. It’s currently trading about 3.61% above its 52-week high.
Beacon Roofing Supply, Inc. (BECN) failed to surprise the stock market in its last reported earnings when it earned $0.93 a piece versus the consensus-estimated $0.94. Its revenue totaled $1.26 billion up 3.88% from the previous quarter.Beacon Roofing Supply, Inc. (NASDAQ:BECN) Intraday View
This stock (BECN) is ahead of its 52-week low with 49.05%. Its last month’s stock price volatility remained 2.75% which for the week stands at 1.96%. The share price has moved forward from its 20 days moving average, trading at a distance of 7.52% and stays 11.68% away from its 50 days moving average. Over the last five days, shares have managed 6.48% gains and now is up 20.85% since hitting its 200-day moving average of $49.16. Beacon Roofing Supply, Inc. (BECN) has made its way to a 12-month gain of 25.78%.
Turning to TG Therapeutics, Inc. (NASDAQ:TGTX), its shares were trading at $7.4 a retreat of $-0.3, on the trading floor. The stock, after opening at $7.7, touched a high of $7.8 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.4. TG Therapeutics, Inc. has 3 buy ratings, 0 holds and 0 sells even after the stock tumbled -51.79% from its high of $15.35 to a $563.58 million market value through last close.
The company’s consensus rating on Reuter’s scale improved from 1.25 to 1.4 during a month. Analysts set a 12-month price target of $27.2 a share. The target implies a 267.57% spike from where the shares are currently trading. Also, the current price highlights a discount of 386.49% to analysts’ high consensus price target.TG Therapeutics, Inc. (NASDAQ:TGTX) Intraday Trading
The counter witnessed a trading volume of 2.49 million shares versus an average volume of 1.24 million shares during last trading session. Its last month’s stock price volatility remained 5.85% which for the week approaches 6.45%. The lowest price the stock reached in the last trading day was $7.3 and compares with the $4.10 52-week low. The stock recovered 80.49% since its low point and has performed 59.14% year-to-date.